SynthesisHeart failure reviews2021
Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
Synthesis in Heart failure reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Association between haemoglobin, albumin, lymphocytes, and platelets and mortality in patients with heart failure.ESC heart failure · 2024Pooled it
- C-Reactive Protein, Interleukin-6, Trimethylamine-N-Oxide, Syndecan-1, Nitric Oxide, and Tumor Necrosis Factor Receptor-1 in Heart Failure with Preserved Versus Reduced Ejection Fraction: a Meta-Analysis.Current heart failure reports · 2023Pooled it
- Risk Prediction Models and Novel Prognostic Factors for Heart Failure with Preserved Ejection Fraction: A Systematic and Comprehensive Review.Current pharmaceutical design · 2023Pooled it
- Effects of statins on functional capacity and cardiac remodeling in patients with heart failure and preserved ejection fraction: a randomized open-label pilot trial.Frontiers in cardiovascular medicine · 2026Trial
- Inflammatory and Genetic Determinants of Functional Status in HFpEF: The Role of Circulating IL-6 andBiomedicines · 2026Article
- Longitudinal inflammatory-metabolic-adiposity burden and incident heart failure across cardiovascular-kidney-metabolic stages: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Even mild elevations of C-reactive protein levels predict long-term prognosis in heart failure with mildly reduced ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Admission C-Reactive Protein and Mortality After STEMI: A Retrospective Cohort Study Identifying Subgroup-Specific Risk Thresholds.Journal of clinical medicine · 2026Article
- Comorbidity-Driven Inflammation in HFpEF: Immune Profiling and Therapeutic Targets.Current heart failure reports · 2026Review
- Inflammatory Biomarkers and Clinical Outcomes in Hospitalized Patients with COVID-19 and Pre-Existing Heart Failure: A Single-Center Cohort Study.Journal of clinical medicine · 2026Article
- Diagnostic and Prognostic Utility of DNI and CRP in Patients with Dilated Cardiomyopathy.International journal of molecular sciences · 2026Article
- CT-derived Epicardial Adipose Tissue Density and Its Association With Systemic Inflammation and Functional Impairment in Heart Failure With Preserved Ejection Fraction: A Prospective Cross-sectional Study From Oman.Journal of the Saudi Heart Association · 2026Article
- Machine learning-based identification of heart failure with reduced ejection fraction using routine laboratory indicators.Frontiers in cardiovascular medicine · 2026Article
- Systemic Immune-Inflammation Index Outperforms Conventional Inflammatory Markers in Predicting Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction.Journal of inflammation research · 2026Article
- The C-reactive protein-to-body mass index ratio predicts prognosis in patients with different types of heart failure.Open medicine (Warsaw, Poland) · 2026Article
- Joint Associations of High-Sensitivity C-Reactive Protein and Albumin with Incident Heart Failure: A Prospective Cohort Study.Journal of inflammation research · 2026Article
- Systemic inflammation and the risk of adverse clinical outcomes in heart failure with preserved ejection fraction.Frontiers in cardiovascular medicine · 2026Article
- C-reactive protein in cardiovascular disease: clinical associations, conformation-dependent biology, and therapeutic perspectives.Frontiers in immunology · 2026Review
- Inflammatory Biomarkers in Heart Failure: Clinical Perspectives on hsCRP, IL-6 and Emerging Candidates.Current heart failure reports · 2025Review
- Prognostic utility of advanced lung cancer inflammation index in heart failure with preserved ejection fraction.ESC heart failure · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a major epidemic with rising morbidity and mortality rates that encumber global healthcare systems. While some studies have demonstrated the value of CRP in predicting (i) the development of HFpEF and (ii) long-term clinical outcomes in HFpEF patients, others have shown no such correlation. As a result, we conducted the following systematic review and meta-analysis to assess both the diagnostic and prognostic role of CRP in HFpEF. PubMed and Embase were searched for studies that assess the relationship between CRP and HFpEF using the following search terms: (((C-reactive protein) AND ((preserved ejection fraction) OR (diastolic heart failure))). The search period was from the start of database to August 6, 2019, with no language restrictions. A total of 312 and 233 studies were obtained from PubMed and Embase respectively, from which 19 studies were included. Our meta-analysis demonstrated the value of a high CRP in predicting the development of not only new onset HFpEF (HR: 1.08; 95% CI: 1.00-1.16; P = 0.04; I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.